POS1162 PREDICTORS OF HOSPITALISATION IN PATIENTS WITH RHEUMATIC DISEASE AND COVID-19 IN IRELAND: DATA FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE PHYSICIAN-REPORTED REGISTRY
Authors: R. Conway, E. Nikiphorou, C. Demetriou, C. Low, K. Leamy, J. Ryan, R. Kavanagh, A. Fraser, J. Carey, P. O’connell, R. Flood, R. Mullan, D. Kane, P. Robinson, J. Liew, R. Grainger, G. Mccarthy
Journal: Annals of the Rheumatic Diseases (2021)

Background: There is limited data regarding the risk of hospitalisation in patients with rheumatic disease and COVID-19 in Ireland. Objectives: We used the COVID-19 Global Rheumatology Alliance (GRA) registry data to study outcomes and their predictors. Methods: We examined data on patients and their disease-related characteristics entered into the COVID-19 GRA provider registry from Ireland (24th March 2020 to 31st August 2020). Multivariable logistic regression was used to assess the association of demographic and clinical characteristics with hospitalisation. Results: Of 105 patients, 47 (45.6%) were hospitalised and 10 (9.5%) died. Multivariable logistic regression analysis showed age (OR=1.06, 95%CI 1.01 to 1.10), number of comorbidities (OR=1.93, 95%CI 1.11 to 3.35), and glucocorticoid use (OR=15.01, 95%CI 1.77 to 127.16) were significantly associated with hospitalisation. A diagnosis of inflammatory arthritis was associated with a lower odds of hospitalisation (OR=0.09, 95%CI 0.02 to 0.32). All significant variable model Most parsimonious model Unadjusted OR (95% CI) Adjusted OR (95%CI)* Adjusted p-value* Adjusted OR (95%CI) &amp; Adjusted p-value &amp; Female 0.45 (0.20-1.02) 0.33 (0.05-2.23) 0.34 (0.09-1.36) 0.128 Age (years) 1.08 (1.05-1.11) 1.04 (0.97-1.10) 0.224 1.06 (1.01-1.10) 0.010 Inflammatory arthritis 0.11 (0.05-0.28) 0.14 (0.02-0.95) 0.044 0.09 (0.02-0.32) &lt;0.001 Connective Tissue Disease and Other 1.56 (0.62 - 3.92) No comorbidities 0.11 (0.04-0.30) 0.76 (0.09-6.58) 0.802 Most common comorbidities COPD / asthma 4.77 (1.23-18.54) 3.09 (0.16-60.07) 0.456 CVD 3.40 (1.31-8.85) 0.11 (0.01-1.88) 0.129 Hypertension 3.71 (1.52-9.08) 0.56 (0.04-7.94) 0.668 Obesity 0.58 (0.10-3.30) Number of comorbidities (Median, IQR) 3.01 (1.92-4.72) 2.99 (0.59-15.02) 0.184 1.93 (1.11-3.35) 0.020 Never Smoker ref. 0.889 Ever Smoker 3.17 (1.18-8.89) 1.19 (0.10-13.68) Medication prior to COVID-19 diagnosis Glucocorticoids 9.26 (1.95-43.89) 18.14 (1.13-290.81) 0.041 15.01 (1.77-127.16) 0.013 csDMARD monotherapy 0.42 (0.17-1.00) b/tsDMARD (monotherapy or in combination with csDMARD) 0.24 (0.10-0.58) 1.36 (0.19-9.72) 0.557 Conclusion: Increasing age, comorbidity burden, and glucocorticoid use were associated with hospitalisation, while a diagnosis of inflammatory arthritis was associated with lower odds of hospitalization. Disclosure of Interests: Richard Conway Speakers bureau: Janssen, Roche, Sanofi, Abbvie, Elena Nikiphorou Speakers bureau: AbbVie, Eli-Lilly, Gilead, Celltrion, Pfizer, Sanofi, Christiana Demetriou: None declared, Candice Low: None declared, Kelly Leamy: None declared, John Ryan: None declared, Ronan Kavanagh: None declared, Alexander Fraser: None declared, John Carey: None declared, Paul O’Connell: None declared, Rachael Flood: None declared, Ronan Mullan: None declared, David Kane: None declared, Philip Robinson Speakers bureau: UCB, Roche, Pfizer, Gilead, Janssen, Novartis, Eli Lilly, Abbvie, Grant/research support from: Abbvie, UCB, Novartis, Janssen, Pfizer, Jean Liew Grant/research support from: Pfizer, Rebecca Grainger Speakers bureau: Pfizer, Cornerstones, Janssen, Novartis, Abbvie, Geraldine McCarthy: None declared.